Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Haemonetics (HAE) Launches SafeTrace Tx in North America

by Zacks Equity Research

Haemonetics (HAE) expands the transfusion management portfolio with SafeTrace Tx, the latest in its transfusion management software product line.

Smith & Nephew's JOURNEY II UK Knee System Executes Surgeries

by Zacks Equity Research

The JOURNEY II UK development is expected to provide a major impetus to Smith & Nephew's (SNN) Orthopedics segment.

HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3

by Zacks Equity Research

Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.

Urmimala Biswas headshot

Thermo Fisher Rides on New Product Suite and Global Growth

by Urmimala Biswas

A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.

    ViewRay Allies With Two Majors in MR-Guided Radiation Therapy

    by Zacks Equity Research

    ViewRay's (VRAY) collective investments from Elekta and Medtronic are conditioned to the consummation of an equity capital hike of at least $75 million.

      CVS Health Set to Acquire Centene's IlliniCare Health Plan

      by Zacks Equity Research

      CVS Health's (CVS) latest collaboration with Centene is set to expand its Medicaid and Medicare Advantage presence in Illinois.

      Here's Why You Should Invest in ResMed (RMD) Stock Right Now

      by Zacks Equity Research

      Investors continue to be optimistic about ResMed (RMD) on its stellar performance.

      Intuitive (ISRG) at a 52-Week High: What's Driving the Stock?

      by Zacks Equity Research

      Intuitive Surgical (ISRG) has been gaining from a series of positive developments of late.

      3 Reasons Why NuVasive (NUVA) Is a Great Growth Stock

      by Zacks Equity Research

      NuVasive (NUVA) is well positioned to outperform the market, as it exhibits above-average growth in financials.

      Veeva Systems (VEEV) Q3 Earnings and Revenues Beat Estimates

      by Zacks Equity Research

      Veeva (VEEV) gains from solid segmental contributions in fiscal third quarter, raises fiscal 2020 view.

      Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

      by Zacks Equity Research

      Investor confidence in Tandem Diabetes (TNDM) stock is at a high, thanks to solid prospects.

      Walgreens, UnitedHealthcare Team Up to Boost Medicare Services

      by Zacks Equity Research

      Walgreens (WBA) partners with UnitedHealthcare to further strengthen the Medicare coverage for its customers.

      NuVasive Gets FDA Nod for CoRoent Small Interlock System

      by Zacks Equity Research

      NuVasive (NUVA) receives the FDA clearance for expanded use of its Interlock system for minimally disruptive spine surgery at multiple levels.

      Henry Schein to Showcase New Dental Offerings at GNYDM

      by Zacks Equity Research

      Henry Schein's (HSIC) suite of solutions, education, & social media activity featuring dental industry leaders to enable dental professionals to explore new options revolutionizing digital dentistry.

      Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan

      by Zacks Equity Research

      The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.

      Dexcom (DXCM) Hits a 52-Week High: What's Driving the Stock?

      by Zacks Equity Research

      Dexcom (DXCM) gains from several positive developments.

      Myriad Genetics' Test Added in Disease Activity Measure List

      by Zacks Equity Research

      Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.

      Hologic (HOLX) Set to Divest Medical Aesthetics Business

      by Zacks Equity Research

      Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.

      NUVA or RMD: Which Is the Better Value Stock Right Now?

      by Zacks Equity Research

      NUVA vs. RMD: Which Stock Is the Better Value Option?

      Haemonetics Launches TEG 6s PlateletMapping Assay Cartridge

      by Zacks Equity Research

      The global commercial availability of the cartridge is likely to bolster Haemonetics' (HAE) TEG portfolio.

      Tandem Diabetes Gets Canadian Nod for t:slim X2 Insulin Pump

      by Zacks Equity Research

      This regulatory clearance is expected to accelerate Tandem Diabetes' (TNDM) global pump shipments and expand its customer base.

      QIAGEN Expands Existing Deal With LabCorp for Better Treatment

      by Zacks Equity Research

      QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.

      Option Care is the Preferred Provider of Haemophilia Treatment

      by Zacks Equity Research

      Option Care Health (BIOS) can currently access all hemophilia factor treatments.

      Here's Why You Should Hold GNC Holdings (GNC) Stock for Now

      by Zacks Equity Research

      Investors can still retain GNC Holdings (GNC) in their portfolio, thanks to solid prospects.

      Safety Notice Issued by Boston Scientific (BSX) for AngioJet

      by Zacks Equity Research

      Boston Scientific (BSX) issues an urgent field safety notice for AngioJet Ultra consoles.